Cleveland Clinic Innovations
Cleveland Clinic Innovations (CCI) is the commercialization arm of the Cleveland Clinic, established in 2000 and based in Cleveland, Ohio. It focuses on transforming the innovative inventions of Cleveland Clinic employees into medical products that benefit patients. CCI aims to create new business opportunities that extend the Cleveland Clinic's capabilities into the commercial market while fostering economic growth in Northeast Ohio and beyond. The organization promotes an inclusive entrepreneurial environment, encouraging participation from a diverse range of stakeholders, including physicians, nurses, researchers, and administrators. CCI employs a comprehensive approach that features deal teams, domain experts, investment funds, and incubation facilities, all designed to support the development and commercialization of new medical technologies. Through these efforts, CCI facilitates the creation of companies and the deployment of advancements in healthcare.
Enspire DBS Therapy
Series B in 2023
Enspire DBS Therapy, Inc. is dedicated to developing a proprietary deep brain stimulation (DBS) therapy aimed at restoring motor function in stroke survivors with disabilities. Founded in 2010 and based in Cleveland, Ohio, the company is currently conducting a Phase I clinical trial to evaluate the effectiveness of its DBS therapy in stroke recovery. The therapy integrates deep brain stimulation with physical rehabilitation techniques, leveraging natural pathways to enhance the effects of both stimulation and therapy. This innovative approach aims to accelerate recovery for stroke patients, offering them improved access to rehabilitation and the potential for greater restoration of motor function.
MediView
Venture Round in 2023
MediView, LLC is a medical device company based in Cleveland, Ohio, established in 2017. The company specializes in developing an augmented reality surgical navigation system designed to enhance the surgical process for healthcare providers. Its primary product, MediView, utilizes extended reality technology to offer real-time, fused-holographic visualization, which aids in the ablation and biopsy of cancerous tumors. This innovative approach allows surgeons to navigate procedures with greater accuracy and efficacy compared to conventional two-dimensional displays. Additionally, MediView's technology supports remote collaboration and telehealth, providing healthcare professionals with valuable insights and the ability to examine patients more effectively using three-dimensional holograms.
Centerline Biomedical
Series B in 2022
Centerline Biomedical, Inc. was founded in November 2014 and is based on technology developed at the Cleveland Clinic. Centerline's mission is to develop advanced navigation systems that initially target interventional vascular procedures.
Cleveland Diagnostics
Series D in 2021
Cleveland Diagnostics, Inc. is a commercial-stage diagnostics company based in Cleveland, Ohio, founded in 2013. The company specializes in the development and commercialization of non-invasive cancer diagnostic tests, focusing on blood-based assays for prostate, breast, and ovarian cancers, with plans to expand into lung cancer and certain neurological diseases. Cleveland Diagnostics employs proprietary solvent interaction analysis technology to investigate protein biomarkers at the structural level, enhancing the specificity and accuracy of its tests. The company has formed a strategic collaboration with Genomic Health to further its mission of improving cancer diagnostics and screening.
Advanced NanoTherapies
Seed Round in 2019
Advanced NanoTherapies, Inc. is a company that specializes in developing medical devices utilizing Sirolimus for the treatment of atherosclerosis and blockages associated with coronary and peripheral artery diseases. Founded in 2018, the company is based in Cleveland, Ohio, and focuses on a unique nanoparticle technology platform aimed at improving drug delivery for cardiovascular and endovascular applications. This innovative technology enhances medication uptake and retention within cells, providing clinicians with safer treatment options for patients suffering from peripheral artery disease. Through its advancements, Advanced NanoTherapies aims to address significant health challenges in the cardiovascular field.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.